Showing 1–6 of 6 results for author: Uno, H

Comparative Effectiveness Research with Average Hazard for Censored Time-to-Event Outcomes: A Numerical Study

Authors: Hong Xiong, Jean Connors, Deb Schrag, Hajime Uno

Abstract: The average hazard (AH), recently introduced by Uno and Horiguchi, represents a novel summary metric of event time distributions, conceptualized as the general censoring-free average person-time incidence rate on a given time window, $[0,τ].$ This metric is calculated as the ratio of the cumulative incidence probability at $τ$ to the restricted mean survival time at $τ$ and can be estimated throug… ▽ More The average hazard (AH), recently introduced by Uno and Horiguchi, represents a novel summary metric of event time distributions, conceptualized as the general censoring-free average person-time incidence rate on a given time window, $[0,τ].$ This metric is calculated as the ratio of the cumulative incidence probability at $τ$ to the restricted mean survival time at $τ$ and can be estimated through non-parametric methods. The AH's difference and ratio present viable alternatives to the traditional Cox's hazard ratio for quantifying the treatment effect on time-to-event outcomes in comparative clinical studies. While the methodology for evaluating the difference and ratio of AH in randomized clinical trials has been previously proposed, the application of the AH-based approach in general comparative effectiveness research (CER), where interventions are not randomly allocated, remains underdiscussed. This paper aims to introduce several approaches for applying the AH in general CER, thereby extending its utility beyond randomized trial settings to observational studies where treatment assignment is non-random. △ Less

Submitted 30 June, 2024; originally announced July 2024.

A Novel Stratified Analysis Method for Testing and Estimating Overall Treatment Effects on Time-to-Event Outcomes Using Average Hazard with Survival Weight

Authors: Zihan Qian, Lu Tian, Miki Horiguchi, Hajime Uno

Abstract: Given the limitations of using the Cox hazard ratio to summarize the magnitude of the treatment effect, alternative measures that do not have these limitations are gaining attention. One of the recently proposed alternative methods uses the average hazard with survival weight (AH). This population quantity can be interpreted as the average intensity of the event occurrence in a given time window t… ▽ More Given the limitations of using the Cox hazard ratio to summarize the magnitude of the treatment effect, alternative measures that do not have these limitations are gaining attention. One of the recently proposed alternative methods uses the average hazard with survival weight (AH). This population quantity can be interpreted as the average intensity of the event occurrence in a given time window that does not involve study-specific censoring. Inference procedures for the ratio of AH and difference in AH have already been proposed in simple randomized controlled trial settings to compare two groups. However, methods with stratification factors have not been well discussed, although stratified analysis is often used in practice to adjust for confounding factors and increase the power to detect a between-group difference. The conventional stratified analysis or meta-analysis approach, which integrates stratum-specific treatment effects using an optimal weight, directly applies to the ratio of AH and difference in AH. However, this conventional approach has significant limitations similar to the Cochran-Mantel-Haenszel method for a binary outcome and the stratified Cox procedure for a time-to-event outcome. To address this, we propose a new stratified analysis method for AH using standardization. With the proposed method, one can summarize the between-group treatment effect in both absolute difference and relative terms, adjusting for stratification factors. This can be a valuable alternative to the traditional stratified Cox procedure to estimate and report the magnitude of the treatment effect on time-to-event outcomes using hazard. △ Less

Submitted 31 March, 2024; originally announced April 2024.

Assessing Delayed Treatment Benefits of Immunotherapy Using Long-Term Average Hazard: A Novel Test/Estimation Approach

Authors: Miki Horiguchi, Lu Tian, Kenneth L. Kehl, Hajime Uno

Abstract: Delayed treatment effects on time-to-event outcomes have often been observed in randomized controlled studies of cancer immunotherapies. In the case of delayed onset of treatment effect, the conventional test/estimation approach using the log-rank test for between-group comparison and Cox's hazard ratio to estimate the magnitude of treatment effect is not optimal, because the log-rank test is not… ▽ More Delayed treatment effects on time-to-event outcomes have often been observed in randomized controlled studies of cancer immunotherapies. In the case of delayed onset of treatment effect, the conventional test/estimation approach using the log-rank test for between-group comparison and Cox's hazard ratio to estimate the magnitude of treatment effect is not optimal, because the log-rank test is not the most powerful option, and the interpretation of the resulting hazard ratio is not obvious. Recently, alternative test/estimation approaches were proposed to address both the power issue and the interpretation problems of the conventional approach. One is a test/estimation approach based on long-term restricted mean survival time, and the other approach is based on average hazard with survival weight. This paper integrates these two ideas and proposes a novel test/estimation approach based on long-term average hazard (LT-AH) with survival weight. Numerical studies reveal specific scenarios where the proposed LT-AH method provides a higher power than the two alternative approaches. The proposed approach has test/estimation coherency and can provide robust estimates of the magnitude of treatment effect not dependent on study-specific censoring time distribution. Also, the proposed LT-AH approach can summarize the magnitude of the treatment effect in both absolute difference and relative terms using ``hazard'' (i.e., difference in LT-AH and ratio of LT-AH), meeting guideline recommendations and practical needs. This proposed approach can be a useful alternative to the traditional hazard-based test/estimation approach when delayed onset of survival benefit is expected. △ Less

Submitted 15 March, 2024; originally announced March 2024.

On sample size determination for restricted mean survival time-based tests in randomized clinical trials

Authors: Satoshi Hattori, Hajime Uno

Abstract: Restricted mean survival time (RMST) is gaining attention as a measure to quantify the treatment effect on survival outcomes in randomized clinical trials. Several methods to determine sample size based on the RMST-based tests have been proposed. However, to the best of our knowledge, there is no discussion about the power and sample size regarding the augmented version of RMST-based tests, which… ▽ More Restricted mean survival time (RMST) is gaining attention as a measure to quantify the treatment effect on survival outcomes in randomized clinical trials. Several methods to determine sample size based on the RMST-based tests have been proposed. However, to the best of our knowledge, there is no discussion about the power and sample size regarding the augmented version of RMST-based tests, which utilize baseline covariates for a gain in estimation efficiency and in power for testing the no treatment effect. The conventional event-driven study design based on the log-rank test allows us to calculate the power for a given hazard ratio without specifying the survival functions. In contrast, the existing sample size determination methods for the RMST-based tests relies on the adequacy of the assumptions of the entire survival curves of two groups. Furthermore, to handle the augmented test, the correlation between the baseline covariates and the martingale residuals must be handled. To address these issues, we propose an approximated sample size formula for the augmented version of the RMST-based test, which does not require specifying the entire survival curve in the treatment group, and also a sample size recalculation approach to update the correlations between the baseline covariates and the martingale residuals with the blinded data. The proposed procedure will enable the studies to have the target power for a given RMST difference even when correct survival functions cannot be specified at the design stage. △ Less

Submitted 15 December, 2022; originally announced December 2022.

Semi-supervised Approach to Event Time Annotation Using Longitudinal Electronic Health Records

Authors: Liang Liang, Jue Hou, Hajime Uno, Kelly Cho, Yanyuan Ma, Tianxi Cai

Abstract: Large clinical datasets derived from insurance claims and electronic health record (EHR) systems are valuable sources for precision medicine research. These datasets can be used to develop models for personalized prediction of risk or treatment response. Efficiently deriving prediction models using real world data, however, faces practical and methodological challenges. Precise information on impo… ▽ More Large clinical datasets derived from insurance claims and electronic health record (EHR) systems are valuable sources for precision medicine research. These datasets can be used to develop models for personalized prediction of risk or treatment response. Efficiently deriving prediction models using real world data, however, faces practical and methodological challenges. Precise information on important clinical outcomes such as time to cancer progression are not readily available in these databases. The true clinical event times typically cannot be approximated well based on simple extracts of billing or procedure codes. Whereas, annotating event times manually is time and resource prohibitive. In this paper, we propose a two-step semi-supervised multi-modal automated time annotation (MATA) method leveraging multi-dimensional longitudinal EHR encounter records. In step I, we employ a functional principal component analysis approach to estimate the underlying intensity functions based on observed point processes from the unlabeled patients. In step II, we fit a penalized proportional odds model to the event time outcomes with features derived in step I in the labeled data where the non-parametric baseline function is approximated using B-splines. Under regularity conditions, the resulting estimator of the feature effect vector is shown as root-$n$ consistent. We demonstrate the superiority of our approach relative to existing approaches through simulations and a real data example on annotating lung cancer recurrence in an EHR cohort of lung cancer patients from Veteran Health Administration. △ Less

Submitted 18 October, 2021; originally announced October 2021.

Combining Breast Cancer Risk Prediction Models

Authors: Zoe Guan, Theodore Huang, Anne Marie McCarthy, Kevin S. Hughes, Alan Semine, Hajime Uno, Lorenzo Trippa, Giovanni Parmigiani, Danielle Braun

Abstract: Accurate risk stratification is key to reducing cancer morbidity through targeted screening and preventative interventions. Numerous breast cancer risk prediction models have been developed, but they often give predictions with conflicting clinical implications. Integrating information from different models may improve the accuracy of risk predictions, which would be valuable for both clinicians a… ▽ More Accurate risk stratification is key to reducing cancer morbidity through targeted screening and preventative interventions. Numerous breast cancer risk prediction models have been developed, but they often give predictions with conflicting clinical implications. Integrating information from different models may improve the accuracy of risk predictions, which would be valuable for both clinicians and patients. BRCAPRO and BCRAT are two widely used models based on largely complementary sets of risk factors. BRCAPRO is a Bayesian model that uses detailed family history information to estimate the probability of carrying a BRCA1/2 mutation, as well as future risk of breast and ovarian cancer, based on mutation prevalence and penetrance (age-specific probability of develo** cancer given genotype). BCRAT uses a relative hazard model based on first-degree family history and non-genetic risk factors. We consider two approaches for combining BRCAPRO and BCRAT: 1) modifying the penetrance functions in BRCAPRO using relative hazard estimates from BCRAT, and 2) training an ensemble model that takes as input BRCAPRO and BCRAT predictions. We show that the combination models achieve performance gains over BRCAPRO and BCRAT in simulations and data from the Cancer Genetics Network. △ Less

Submitted 31 July, 2020; originally announced August 2020.